Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Harvard Business School
McKesson
Medtronic
Merck

Last Updated: December 4, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VORINOSTAT

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for vorinostat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005634 ↗ Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Completed National Cancer Institute (NCI) Phase 1 2000-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced primary or metastatic solid tumors that have not responded to previous therapy.
NCT00005634 ↗ Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Completed Memorial Sloan Kettering Cancer Center Phase 1 2000-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced primary or metastatic solid tumors that have not responded to previous therapy.
NCT00007345 ↗ Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma Completed National Cancer Institute (NCI) Phase 2 2001-03-08 Background: NSC630176 is a depsipeptide fermentation product from Chromobacterium violaceum with potent cytotoxic activity against human tumor cell lines and in vivo efficacy against both human tumor xenografts and murine tumors (1-3). NSC 630176, herein referred to as depsipeptide, shows a lack of cross resistance with several commonly used cytotoxic agents such as vincristine, 5-fluorouracil, mitomycin C and cyclophosphamide (2). However, it has been defined as a P-glycoprotein (Pgp) substrate by COMPARE analysis of the National Cancer Institute (NCI) drug screen cytotoxicity profile (4). Depsipeptide is a member of a novel class of antineoplastic agents, the histone deacetylase inhibitors. In the phase I trial conducted at the National Cancer Institute (NCI), responses were observed at the maximum tolerated dose (MTD) in patients with cutaneous and peripheral T-cell lymphoma. Objectives: In patients with cutaneous T-cell lymphoma, the primary end points to be examined are overall response rate, complete response rate and duration of response. In patients with relapsed peripheral T-cell lymphoma, the endpoints to be examined are overall response rate and complete response rate. To evaluate the tolerability of depsipeptide with extended cycles of therapy. Eligibility: Patients with cutaneous T-cell lymphoma (mycosis fungoides or Sezary syndrome) or other peripheral T-cell lymphomas are eligible. Design: Depsipeptide will be administered at 14 mg/m^2, over 4 hours on days 1, 8 and 15. This trial will accrue in six cohorts; Arm 1, patients with cutaneous T-cell lymphoma who have had less than or equal to two prior cytotoxic chemotherapy regimens; Arm 2, patients with peripheral T-cell lymphoma who have had less than or equal to two prior cytotoxic chemotherapy regimens; Arm 3, patients with cutaneous and peripheral T-cell lymphoma who have had more than two prior cytotoxic chemotherapy regimens; Arm 4, patients with other mature T-cell lymphomas; Arm 5, a replicate arm of arm 1; Arm 6, patients with peripheral T-cell lymphoma who have had more than two prior cytotoxic chemotherapy regimens; Arm 7, patients with cutaneous T cell lymphoma who have received vorinostat. Dose may be adjusted based on toxicities.
NCT00045006 ↗ Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed National Cancer Institute (NCI) Phase 1 2001-07-01 RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced cancer.
NCT00045006 ↗ Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed Memorial Sloan Kettering Cancer Center Phase 1 2001-07-01 RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced cancer.
NCT00106626 ↗ Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors Completed Merck Sharp & Dohme Corp. Phase 1 2005-08-01 The purpose of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with standard doses of pemetrexed and cisplatin for the treatment of advanced solid tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for vorinostat

Condition Name

Condition Name for vorinostat
Intervention Trials
Lymphoma 23
Multiple Myeloma 14
Unspecified Adult Solid Tumor, Protocol Specific 12
Breast Cancer 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for vorinostat
Intervention Trials
Lymphoma 60
Leukemia 42
Leukemia, Myeloid, Acute 31
Leukemia, Myeloid 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for vorinostat

Trials by Country

Trials by Country for vorinostat
Location Trials
United States 756
Canada 45
Japan 21
Australia 18
United Kingdom 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for vorinostat
Location Trials
Texas 55
California 54
Pennsylvania 43
New York 42
Maryland 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for vorinostat

Clinical Trial Phase

Clinical Trial Phase for vorinostat
Clinical Trial Phase Trials
Phase 4 1
Phase 3 8
Phase 2/Phase 3 3
[disabled in preview] 252
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for vorinostat
Clinical Trial Phase Trials
Completed 142
Terminated 54
Active, not recruiting 30
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for vorinostat

Sponsor Name

Sponsor Name for vorinostat
Sponsor Trials
National Cancer Institute (NCI) 96
Merck Sharp & Dohme Corp. 90
M.D. Anderson Cancer Center 22
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for vorinostat
Sponsor Trials
Other 303
Industry 145
NIH 107
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Baxter
Colorcon
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.